NASDAQ$PRAX
Praxis Precision Medicines I · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Praxis Precision Medicines reported financial results, providing a corporate update.
Praxis Precision Medicines reported a net loss of $41.2 million for Q4 2022, with cash and investments of $100.5 million as of December 31, 2022. The company anticipates topline results for the ulixacaltamide Essential1 study in Q1 2023 and data from its clinical-stage epilepsy programs throughout 2023.
- Praxis expects topline results from the ulixacaltamide (PRAX-944) Essential1 study for essential tremor in Q1 2023.
- Topline results are expected for each of three clinical-stage epilepsy programs in 2023.
- PRAX-562 Phase 2 EMBOLD Study results in DEEs are expected in 2H23.
- Cash and investments totaled $100.5 million as of December 31, 2022, supporting operations into 1Q24.
Headline financials
Revenue & EPS history
Praxis · Revenue · Quarterly
$0
Revenue by segment
Praxis · $500K total across 1 segment · Q3 2023
- Collaboration Revenue$500K—100.0%
Forward guidance
Praxis Precision Medicines anticipates several milestones in 2023, including topline results from clinical trials and advancement of development candidates.
Tailwinds
- Topline results from ulixacaltamide (PRAX-944) Essential1 study expected in 1Q23.
- PRAX-222 first-in-patient EMBRAVE Study safety data expected mid-2023.
- PRAX-628 first-in-human Phase 1 data expected mid-2023.
- PRAX-562 Phase 2 EMBOLD Study results expected in 2H23.
- Nomination of a development candidate for PRAX-080 for PCDH19 expected in the second half of 2023.
Headwinds
- Uncertainties inherent in clinical trials.
- Expected timing of submissions for regulatory approval or review by governmental authorities.
- Regulatory approvals to conduct trials.
- Praxis’ ability to continue as a going concern.
- Risks concerning Praxis’ programs and operations as described in its Annual Report on Form 10-K.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-0.3%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-4.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+22.3%
Q2 2022
Best reaction
-40.6%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | -6.4% | -22.2% | |
| Q4 2025 | +0.5% | +4.2% | -9.3% | |
| Q3 2025 | -4.7% | -2.2% | +44.4% | |
| Q1 2025 | +0.2% | -3.5% | +16.3% | |
| Q4 2024 | -40.6% | -41.8% | -40.6% | |
| Q3 2024 | +3.6% | +16.6% | -4.0% | |
| Q2 2024 | -1.1% | +2.0% | +13.3% | |
| Q1 2024 | -5.9% | -6.9% | -15.8% | |
| Q4 2023 | +6.3% | +2.3% | -7.3% | |
| Q3 2023 | +1.4% | -0.6% | +21.6% | |
| Q2 2023 | +10.8% | +17.0% | +43.9% | |
| Q1 2023 | -2.8% | -1.9% | -7.7% | |
| Q4 2022 | -4.2% | -13.0% | -77.0% | |
| Q3 2022 | -12.5% | -11.2% | -13.3% | |
| Q2 2022 | +22.3% | +33.2% | -3.4% | |
| Q1 2022 | +14.0% | +28.1% | -77.7% | |
| Q4 2021 | -1.9% | -4.2% | -22.9% | |
| Q3 2021 | +2.4% | +2.0% | -17.1% | |
| Q2 2020 | +12.7% | +35.9% | +42.8% | |
| Q2 2021 | +12.7% | +35.9% | +42.8% | |
| Q1 2021 | -16.4% | -16.1% | -20.2% | |
| Q4 2020 | -6.8% | -11.5% | -34.0% | |
| Q3 2020 | +2.3% | +18.2% | +54.7% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro